3 August 2026 – Minneapolis, MN, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX: IMR) is pleased to announce the launch of Imricor Cardiovascular, a new vertical that expands the interventional MR (iMR) market for Imricor alongside its electrophysiology and ablation business. Following recent FDA clearances for NorthStar® and the Vision-MR® Diagnostic Catheter, Imricor Cardiovascular gives U.S. … Read More
FDA Clears NorthStar Mapping System
2 February 2026 – Minneapolis, MN, Imricor Medical Systems, Inc. (Company or Imricor) (ASX: IMR) is pleased to announce that the United States Food and Drug Administration (FDA) has granted 510(k) clearance for the Company’s NorthStar® Mapping System under the premarket notification process. NorthStar is the first and only MRI-Native 3D mapping and guidance system to receive FDA clearance, setting a new standard … Read More